GlassScriptPhysician profile
Lindsay D Rerko
NPI 1184864431
$7,716.09
in general payments reported to CMS, 2019-2025
56 companies · $1,325 in 2025
The $1,325 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $295 · 2021: $1,230 · 2022: $1,395 · 2023: $1,259 · 2024: $1,680 · 2025: $1,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,263.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,425.06 | 2019-2025 | |
| Novo Nordisk INC | $1,008.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $782.00 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $663.04 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $612.51 | 2019-2025 | |
| Glaxosmithkline, LLC. | $368.44 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $244.23 | 2022-2025 | |
| Astellas Pharma US INC | $210.62 | 2019-2025 | Veozah |
| Abbott Laboratories | $208.45 | 2019-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.96 | 2019-2025 | Jardiance, Spiriva Respimat |
| Amgen INC. | $174.11 | 2019-2025 | Evenity, Prolia, Repatha |
| Exact Sciences Corporation | $152.68 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $141.38 | 2019-2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.90 | 2019-2024 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $96.73 | 2024-2025 | Auvelity, Sunosi, Symbravo |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Rerko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.